FRAMINGHAM, Mass., Sept. 16, 2021 /PRNewswire/ -- BERG, a clinical-stage biotech that employs patient biology and artificial intelligence (AI) to research diseases and develop innovative treatments, today announced its participation at the European Society for Medical Oncology (ESMO) 2021 Congress, from September 16-21, 2021. At the event, the company will unveil its most recent medical and clinical research developments for pancreatic ductal adenocarcinoma (PDAC) as part of its Project Survival® longitudinal prospective clinical trial with Beth Israel Deaconess Medical Center (BIDMC), a research and teaching affiliate of Harvard Medical School (HMS).
Search / 76 results found Showing: 1-10 of 76
ALLSTON, Mass., Sept. 16, 2021 /PRNewswire/ -- Elevian, an emerging biotech company developing medicines that restore youthful regenerative capacity with the potential to treat and prevent multiple age-related diseases, today announced that it raised $40 million in an oversubscribed Series A round led by Prime Movers Lab. The funding will enable Elevian to submit an investigational new drug application, scale manufacturing and complete Phase 1 clinical trials for its lead indication of stroke recovery.
BOSTON, Sept. 15, 2021 /PRNewswire/ -- Remedium Bio, Inc., a biotechnology company developing novel gene therapies, is proud to announce it has entered into a Sponsored Research Agreement with Tufts University's foremost Rheumatology laboratory to complete pre-clinical efficacy studies on Remedium's lead gene therapy candidate, a single-injection potentially disease-modifying Osteoarthritis treatment. The research is being led by Dr. Li Zeng, PhD, Associate Professor of Immunology at Tufts University School of Medicine, whose laboratory has developed in vitro, ex vivo, and in vivo testing capabilities for Osteoarthritis (OA). Dr. Zeng is well-known for her extensive expertise in preclinical Rheumatology. Her laboratory has generated high-impact publications in journals including Nature Scientific Reports, Nature Laboratory Investigations, Development, Journal of Clinical Investigations, and Osteoarthritis and Cartilage.
CAMBRIDGE, Mass., Sept. 14, 2021 /PRNewswire/ -- QurAlis Corporation, a biotech company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, today announced the nomination of QRL-201 as the Company's development candidate for the treatment of ALS. A first-in-class molecule that aims to restore STATHMIN-2 (STMN2) expression in ALS patients, QRL-201 is currently undergoing investigational new drug (IND)-enabling studies. QurAlis plans to initiate clinical development for QRL-201 the second half of 2022.
BOSTON, Sept. 14, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today that multiple abstracts have been accepted for presentation at several leading ophthalmic conferences this fall. These abstracts feature novel clinical findings from the positive ReCLAIM trial, which evaluated elamipretide in patients with dry age-related macular degeneration (AMD), as well as clinical updates from the ongoing ReCLAIM-2 study in patients with extrafoveal, or non-central, geographic atrophy (GA) due to dry AMD. The design and inclusion criteria for ReCLAIM-2 were informed by the positive signals in patients with extrafoveal GA enrolled in the ReCLAIM study, which also demonstrated that patients with better baseline mitochondrial health experienced greater improvements in visual function following six months of elamipretide therapy.
BOSTON, Sept. 13, 2021 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced today that Brazil's National Health Surveillance Agency (ANVISA) has approved FERRIPROX® (deferiprone) for the treatment of iron overload in patients with sickle cell disease (SCD) or other anemias.
LEXINGTON, Mass., Sept. 10, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that president and chief executive officer Fred Chereau will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021. The on-demand presentation will be available at 7:00 a.m. ET on Monday, September 13, 2021.
In times of crisis, small things matter.
BOSTON, Sept. 7, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at two upcoming virtual investor conferences in September: